New Enterprise Associates is a prominent venture capital firm focusing on investments in technology and healthcare startups. They help entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from the seed stage through the IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

New Enterprise Associates

F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.  Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.   Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

F-Prime Capital

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Atlas Venture

The Innovation Fund was created in 2007 by Brigham and Women's Hospital and Massachusetts General Hospital to address a growing unmet need for funding emerging technology in the capital gap between invention and product development.  The main objective of the fund is to accelerate to market technologies developed by Partners HealthCare investigators, thereby enhancing healthcare quality, cost and outcomes. Structured as a separate LLC entity, the $35M Fund is evergreen in design and will reinvest all gains from investments back into the Fund to create capital for additional investments.  Investment decision oversight is provided by an independent external committee composed of experts from industry, venture capital and academia.  The Fund operates on a venture capital model whereby opportunities are rigorously evaluated on the basis of scientific strength as well as potential for commercial success.  The Fund has four major goals:  * Capture more value from the PHS research portfolio by creating companies, technologies and solutions that advance and enhance healthcare. * Provide funding for technologies positioned in the capital gap between invention and clinical development. * By demonstrating institutional commitment, attract external capital that will leverage and encourage co-investment. * Generate a return on investment to refresh the fund and provide capital for additional technologies.  Gap Funding Over the last five to seven years, the environment for early-stage investing has undergone significant change. As a result of these changes, there is a dearth of funding support for technologies/companies positioned between invention and clinical development. By focusing on this capital gap, the Fund can advance technologies of high commercial potential and medical benefit to a stage where larger, more traditional investment sources are attracted to underwrite the risk.  Types of Fund Investments The Partners Innovation Fund will make two types of investments: Equity and Development.  Equity investments are seed and early financings that will catalyze company formation. These investments will often be a Series A stock and co-investors are frequently other early institutional investors, private investors or corporate investment funds.  Development investments precede company formation and are intended to validate technologies with a high potential for later commercialization by either new venture formation or out-licensing to an existing market player.  For all investments, funds will be reserved for participation in follow-on investments.  Innovation Fund Process  Utilizing a proven venture capital based diligence model, the team conducts in-depth diligence on all opportunities in two steps:  1. Initial Screening: Assesses opportunities for high commercial potential. Key project attributes are:  * Product concept and value proposition * Intellectual Property Position * Stage of technology development * Market Opportunity * Technology Review * Management Team * Regulatory pathway * Funding requirements * Competitive Analysis * Business Model   2. Evaluation and Investment Decision: During this step, PIF staff conducts extensive diligence to assess the strength of the proposed business in relation to our investment criteria. This process takes place over 3 to 6 months during which time we interact with technical and market experts, possible customers, competitors and potential co-investors as we prepare for presentation of the investment opportunity to our external Investment Committee for final approval.  The team will work with investigators and their advisors to develop a project or business plan including connections to potential entrepreneurs, advisors and investors in the venture, private or corporate arena.  Venture Launch / Ongoing Support: Once an investment has been approved, the Innovation Fund plays an active role in the ongoing development of the new venture. The team will work on all aspects required to move the new entity forward including recruiting senior management and staff, providing guidance and support in technology development, serving on the Board of Directors and working with management to achieve milestones.

Partners Innovation Fund

Lonza Group AG, a Life Sciences driven chemical company, supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalogue of organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds and composites. The company operates in three divisions that include Exclusive Synthesis & Biopharmaceuticals; Organic Fine & Performance Chemicals; and Polymer Intermediates. Exclusive Synthesis & Biopharmaceuticals In the area of Exclusive Synthesis and Biopharmaceuticals, Lonza is the custom manufacturing for the global life sciences companies. In addition to Lonza's traditional chemical custom manufacturing, Lonza offers microbial custom fermentation and biotransformation services. Lonza Biologics is focused on the production of therapeutic monoclonal antibodies and recombinant proteins produced by mammalian cell cultures. Exclusive chemical synthesis: Exclusive chemical synthesis engages in the process development and manufacture of intermediates and active ingredients. It is used in Life sciences industry, pharmaceuticals and animal health products. Exclusive microbial fermentation and biotransformation: Exclusive microbial fermentation and biotransformation processes development and manufactures intermediates, active ingredients and biopharmaceuticals. Its products are used Life sciences industry, pharmaceuticals and cosmetics. The company also offers L-Carnitine (L-Carnipure), which is applicable in sports nutrition, food, pharmaceuticals and feedstuffs. Exclusive microbial biopharma fermentation: Exclusive microbial biopharma fermentation engages in the process development and manufacture of therapeutic recombinant proteins and antibody fragments. It is used in pharmaceutical and biotechnology industry. Exclusive mammalian cell fermentation: Exclusive mammalian cell fermentation engages in the process development and manufacture of therapeutic monoclonal antibodies and recombinant proteins, proprietary GS-expression system, which are used in the pharmaceutical and biotechnology industry. Organic Fine & Performance Chemicals In the area of organic fine and performance chemicals, the company develops, manufactures, and sells various organic chemical intermediates applied in pharmaceuticals, agrochemicals, vitamins, food and feed, dyes, pigments, adhesives, and fragrances, as well as polymers. The sector performance chemical is mainly engaged in the development and production of biocides and oleochemicals. These core activities are supplemented by the polymer intermediates business, including additives, unsaturated polyester resins, compounds, and composites. Organic Fine Chemicals: The company offers Niacin, niacinamide, Diketene derivatives, Hydrocyanic acid derivatives, Engineering polymer additives and Meta â€“ Metaldehyde. Its products are used in food and feedstuffs, pharmaceuticals, agrochemicals, colorants Vitamins, optical brighteners, agrochemicals, electronics, aerospace industry, and coating Snail. Performance Chemicals: The company offers microbiologically active substances, such as Quaternary ammonium, compounds, Halogenated hydantoins; and Hydantoin derivatives. It also offers Oleochemical derivatives. The company's products are used by the disinfectants for household, industrial and institutional applications, including water treatment and wood preservation; biocides for water treatment, pools and spas, and household disinfection; preservatives for personal care and household products; and food ingredients, humectants and emollients for personal care, processing aids and lubricants for polymer and textile industry, and industrial defoamers.

Lonza

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.

Alexandria Venture Investments

Farallon Capital Management, L.L.C. is an American capital management firm that manages funds on behalf of institutions and individuals with significant capital. Based in San Francisco, the firm was founded by Thomas F. Steyer in March of 1986. As of September 2008, it has around 150 employees.  While it invests across the capital structure and in all asset classes, a large amount of its investments are in risk arbitrage, restructuring and recapitalization. Investments include public and private debt and equity securities, direct investments in private companies, and real estate. Farallon's real estate investments span the United States, Europe, Latin America and India.

Farallon Capital Management

EcoR1 Capital is an investment advisory firm focused on the biotech industry. They aim to identify and evaluate innovative therapeutic solutions that can bring significant improvements to patients' lives. Drawing inspiration from the transformative power of the EcoR1 restriction enzyme in the biomedical field, they invest in biotech companies that offer promising new treatments for untreated diseases. EcoR1 Capital recognizes the importance of building upon the innovative contributions of its predecessors in order to continue advancing medical research.

EcoR1 Capital

Google Ventures invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, Google Ventures focuses on long-term investments. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering and help them connect with Google for technology and expertise. Founded in 2009 as Google Ventures, Google Ventures manages over $8 billion in assets with 400 active portfolio companies in North America and Europe. Some notable investments include Uber, Nest, Slack, GitLab, and One Medical. Google Ventures is based in the San Francisco Bay Area with offices in Cambridge, New York, and London.

Google Ventures

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. The company invests in companies with promising technologies and products.

RA Capital Management

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.

Perceptive Advisors

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments.  Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management.

Casdin Capital

Avidity Partners is an investment management firm that offers financial services.

Avidity Partners

Woodline Partners is a private equity firm that focuses on the healthcare and technology sectors. The firm was founded in 2018 and is based in San Francisco, California, United States.

Woodline Partners

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham that invests in early-stage companies. The primary mission of MGB Ventures is to accelerate the translation of innovative research and technology developed within the Mass General Brigham system into commercial solutions that can significantly improve patient care and healthcare delivery.

Mass General Brigham Ventures

Octagon Capital invests in public and private healthcare companies globally. Octagon Capital focuses on strategic long-term investments and strive to work with our portfolio management teams as partners.

Octagon Capital Advisors

TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCG X has investment teams in Palo Alto and New York City

TCG Crossover

Affinia Therapeutics

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

Affinia Therapeutics is a developer of adeno-associated virus (AAV) gene-based therapies used to treat patients diagnosed with diseases related to the nervous system, heart, and muscle. Specifically, the muscle diseases Affinia develops therapeutics for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and cystic fibrosis (CF). The company has developed a proprietary Affinia rationally-designed therapies platform (ART), which it uses to develop and design its gene therapeutics.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer

Affinia Therapeutics is a developer of adeno-associated virus (AAV) gene-based therapies used to treat patients diagnosed with diseases related to the nervous system, heart, and muscle. Specifically, the muscle diseases Affinia develops therapeutics for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and cystic fibrosis (CF). The company has developed a proprietary Affinia rationally-designed therapies platform (ART), which it uses to develop and design its gene therapeutics.As of May 2024, the company had not publicly disclosed its pipeline of therapeutic candidates.Key customers and partnershipsAffinia partnered with Vertex Pharmaceuticals in April 2020 to collaborate on creating and developing AAV capsids for gene therapies. Through the partnership, Affinia would use its proprietary AAVSmart Library and expertise, while Vertex would use its clinical and regulatory experience to develop therapies for individuals diagnosed with DMD, DM1 and CF.

<div>
 
 Tenaya Therapeutics is a developer of therapeutics for heart disease. The company develops its therapeutics using precision medicine, gene therapy, and cellular regeneration. Tenaya produces therapeutics that also use proprietary in-vivo and in-vitro models. Additionally, the company has developed in-house adeno-associated virus (AAV) capsid engineering capabilities and has screened over one billion variants from more than 30 diverse, proprietary AAV libraries. The company is publicly listed on the Nasdaq and trades under the ticker symbol TNYA.&nbsp;&nbsp;
 
 
 In October 2023 Tenaya Therapeutics (Tenaya) received FDA clearance for the company&rsquo;s investigational new drug application (TN-401) to initiate clinical testing. TN-401 is Tenaya&rsquo;s adeno-associated virus serotype 9-based investigational gene therapy drug candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy caused by mutations in the plakophilin-2 gene. 
 
 
 As of May 2024, the company&rsquo;s clinical pipeline included two candidates in Phase I clinical trials, a gene therapeutic for the treatment of Hypertrophic Cardiomyopathy, and a small molecule inhibitor for the treatment of heart failure with preserved ejection fraction. Additionally, Tenaya had one gene therapy candidate and two genetic medicine candidates in preclinical testing phases, along with five genetic medicine candidates in the discovery stage. 
 
 
 
</div>

Tenaya Therapeutics

<div>
 
 Sarepta Therapeutics is a gene therapy provider for conditions such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy 
 (LGMD), and Charcot-Marie-Tooth Disease. The company&rsquo;s therapeutics incorporate technology related to gene therapy, RNA technologies, and gene editing. The company leverages a proprietary phosphorodiamidate morpholino oligomer (PMO) platform for the development of its RNA-based therapeutics. As of August 2023, the company had four FDA-approved treatments for DMD: ELEVIDYS, EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta Therapeutics is also listed on the Nasdaq, trading under the symbol SRPT.&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 As of May 2024, the company had several RNA, gene, and gene editing therapeutics in various clinical stages. Sarepta had two RNA therapeutics, both for the treatment of DMD, one in clinical testing, and the other in pre-clinical testing. Additionally, the company had six gene therapeutics, one for the treatment of DMD (both in clinical testing), four for the treatment of LGMD (three in clinical testing, one in preclinical testing) and one for multiple targets (in preclinical testing). Also, Sarepta had two gene editing-based therapeutics in development for the treatment of DMD, both in preclinical testing phases. 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Over the years since its founding, Sarepta has partnered with several industry and academic partners. The list includes Dyno Therapeutics, Genethon, Genevant Sciences, Hansa Biopharma, Roche, Columbia University, Harvard University, Translational Laboratory of Murdoch University, University of Florida College of Medicine, The Abigail Wexner Research Institute at Nationwide Children&rsquo;s Hospital, University of Massachusetts Medical School, and the University of Western Australia.&nbsp;&nbsp;
 
 
 
 
 In October 2021, Sarepta and healthcare giant Roche announced they would collaborate on carrying out a clinical study of Sarepta&rsquo;s therapeutic candidate SRP-9001 for the treatment of DMD.&nbsp;
 
 
 
 
 Sarepta and pharmaceutical company Catalent announced that in January 2023, the companies were signing a commercial supply agreement. Through the agreement,&nbsp; Catalent would manufacture Sarepta&rsquo;s gene therapeutic for the treatment of DMD; delandistrogene moxeparvovec (SRP-9001).
 
 
 
</div>

Sarepta Therapeutics

<div>
 
 Mesoblast is a cell therapy manufacturer that provides therapeutics for oncology, cardiovascular, orthopedic, hematology, immunity, and inflammation-related conditions. The company is listed on the Australian Stock Exchange and trades under the ticker symbol &ldquo;MSB.&rdquo; Mesoblast develops therapeutics using its proprietary mesenchymal lineage cell technology platform, which is used to produce cryopreserved, off-the-shelf, and cellular-based solutions. The company also incorporates 3D bioreactor technology and automation into its production process to produce higher yields.&nbsp;
 
 
 
 
 As of May 2024, the company had five candidates that are in various stages of clinical testing. Mesoblast&rsquo;s steroid-refractory candidate for Acute Graft Versus Host Disease is currently in late-stage Phase III clinical testing and is the closest candidate to commercialization. The company&rsquo;s drug candidates for acute respiratory distress syndrome, chronic low back pain, and chronic heart failure and reduced ejection fraction are also in Phase III clinical testing while its candidate for inflammatory bowel disease is in Phase II of clinical testing.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured several agreements with international companies with regard to development and commercialization of Mesoblast&rsquo;s candidates, including Gr&uuml;nenthal GmBH, JCR Pharmaceuticals, Tasly Pharmaceutical Group, TiGenix NV, and the Lonza Group.&nbsp;
 
 
 
 
 Additionally, in April 2020, Mesoblast partnered with The US NIH&rsquo;s National Heart, Lung, and Blood Institute to conduct testing of its allogeneic mesenchymal stem cell (MSC) product candidate, &ldquo;remestemcel-L.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 
</div>

Mesoblast

<div>
 
 Ocugen is a gene therapy manufacturer that develops vaccine, cell, and gene-based therapeutics for infectious, eye, and orthopedic diseases. Its cell therapy includes a three dimensional tissue-engineered cartilage disk through the growth of chondrocytes &ndash; the cells responsible for maintaining cartilage health. Its gene therapy solution consists of creating a copy of the patient&rsquo;s gene in order to replace mutated/damaged genes. The company is publicly listed on the Nasdaq, and trades under the symbol &lsquo;OCGN&rsquo;.&nbsp;
 
 
 As of May 2024, the company had five therapeutic solutions being clinically tested. The company was developing four gene therapies for the treatment of retinitis pigmentosa, Leber congenital amaurosis, geographic atrophy, and orphan disease. Its treatment candidate for retinitis pigmentosa was in Phase III of clinical study, while its other gene therapies were in Phase I/II. 
 Ocugen was also developing a biological material, in the IND stage, for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The company's cell therapy for the treatment of articular cartilage defects in the knee was in Phase III of clinical study. Finally, the company was also developing three vaccines, all in IND stages, for prevention of diseases caused by the flu, Covid-19, and a combination of the flu and Covid-19.
 
 
 Key customers and partnerships
 
 
 Ocugen partnered with biopharmaceutical manufacturer Jubilant HollisterStier of Spokane in June 2021 to manufacture its Covid-19 therapeutic COVAXIN. Through the partnership, Jubilant would be the potential commercial manufacturer of Ocugen&rsquo;s vaccine for the US and Canadian markets.
 
 
 
 
 
</div>

Ocugen

<div>
 
 MeiraGTx is a developer of gene therapies that aim to treat ocular diseases and problems, neurodegenerative disorders, and salivary gland and autoimmune disorders. MeriaGTx is also developing riboswitch-inducible expression programs for the treatment of inherited obesity and Wilson disease, along with producing small-molecule riboswitch inducers. The company is listed on the Nasdaq and trades under the symbol MGTX.&nbsp;&nbsp;
 
 
 As of May 2024, the company had four gene-based therapeutic candidates in Phase II of their clinical trials for the treatment of (1) xerostomia, Parkinson's Disease, and RPE65-Associated retinal dystrophy and (2) achromatopsia. The company also had one therapeutic being developed to treat Sjogren&rsquo;s Syndrome that was in Phase I/II of its clinical trials. Additionally, MeiraGTx had seven other therapeutics in discovery/preclinical stages. The company was also developing a therapeutic for X-linked retinitis pigmentosa in collaboration with Janssen, which was in Phase III of clinical trials. 
 
 
 Key customers and partnerships
 
 
 MeiraGTx partnered with the International Institute of Risk and Safety Management (IIRSM) in November 2022 to influence risk agendas, raise awareness, the standards of risk, and safety management across the industry.&nbsp;
 
 
 Funding and financials
 
 
 Meira last raised funds in October 2023, when the company secured a strategic investment of USD 30 million from Sanofi. As part of the transaction, Sanofi was granted the right of first negotiation for MeiraGTx's gene regulation technology in certain targets.&nbsp;
 
 
 
</div>

MeiraGTx

Companies producing cells, genes, tissues, and biomaterials such as exosomes and extracellular matrix for drug developers and pharmaceutical companies developing regenerative medicine

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering T cells to target and kill cancer cells

Companies conducting R&D on therapies that modify or introduce new genes into the body to treat diseases

Includes therapies that use cells (other than CAR-T and stem cells) such as Adipose-Derived Regenerative Cells (ADRCs), cardiosphere-derived cells, and gamma delta T cells (GDT cells)

Stem cell therapy involves using stem cells usually extracted from the bone marrow and umbilical cord blood to repair a variety of diseases

Startups in the hub consider individual patient profiles, involving variability in genes, environment, and lifestyle

Genomics helps understand the genetic information stored in the DNA to develop targeted treatments

Affinia Therapeutics

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless